NICE Technology Appraisal Guidance No.81; Frequency of application of topical corticosteroids for atopic eczema

Static List Review

TA81; Frequency of application of topical corticosteroids for atopic eczema was added to the static list in December 2007.

Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research or evidence available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further review consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.

As the appraisal has been on the static list for more than 5 years, NICE has been gathering intelligence to ascertain whether there is any new evidence available relevant to this appraisal and whether this should be considered through the full review proposal process.

There have been some small changes to the list prices of the technologies, but we note that the current guidance states, “where more than one alternative topical corticosteroid is considered clinically appropriate within a potency class, the drug with the lowest acquisition cost should be prescribed, taking into account pack size and frequency of application”.  This indicates that a review of the guidance would be unlikely to lead to a change in the existing recommendations. There is no other new evidence available that would warrant a review at this time.

As a result, we are contacting stakeholders who were involved in the last review proposal for this appraisal to inform them that we have decided that TA81 should remain on the static list and no further action is required at this time.

However, if NICE is notified of a significant change to the evidence base at any stage in the future, this could trigger a formal review proposal.

May 2014

Attachments